XML 45 R35.htm IDEA: XBRL DOCUMENT v3.23.3
General - Schedule of Error Corrections and Prior Period Adjustments (Details) - USD ($)
$ / shares in Units, $ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Jun. 30, 2023
Mar. 31, 2023
Sep. 30, 2022
Jun. 30, 2022
Mar. 31, 2022
Sep. 30, 2023
Sep. 30, 2022
Dec. 31, 2022
Balance Sheet for September 30, 2022 (unaudited)                  
Additional paid-in capital $ 518,607           $ 518,607   $ 451,608
Accumulated deficit (494,026)           (494,026)   $ (457,484)
Consolidated Statement of Operations and Comprehensive Loss for the three months ended September 30, 2022 (unaudited)                  
Research and development expenses 4,662     $ 4,065     12,793 $ 14,152  
Selling, general and administrative expenses 6,195     4,779     15,147 13,477  
Total operating expenses 10,857     8,844     27,940 27,629  
Operating loss (10,556)     (8,173)     (26,878) (25,998)  
Net loss (20,340) $ (7,202) $ (9,000) (8,877) $ (10,159) $ (9,000) (36,542) (28,036)  
Total other comprehensive loss $ (20,335)     $ (8,923)     $ (36,518) $ (28,118)  
Basic loss per common share (in dollars per share) $ (1.14)     $ (0.96)     $ (2.61) $ (3.29)  
Diluted loss per common share (in dollars per share) $ (1.14)     $ (0.96)     $ (2.61) $ (3.29)  
Consolidated statement of Stockholders’ Equity (Deficit) for the three months ended September 30, 2022 (unaudited)                  
Compensation expense for issuance of stock options $ 2,783 1,661 1,661 $ 1,627 2,119 2,271      
Net loss (20,340) (7,202) (9,000) (8,877) (10,159) (9,000) $ (36,542) $ (28,036)  
Consolidated Statement of Cash Flows for the nine months ended September 30, 2022 (unaudited)                  
Net loss $ (20,340) $ (7,202) $ (9,000) (8,877) $ (10,159) $ (9,000) (36,542) (28,036)  
Stock option compensation expense             $ 6,152 6,016  
As previously reported                  
Balance Sheet for September 30, 2022 (unaudited)                  
Additional paid-in capital       442,066       442,066  
Accumulated deficit       (447,341)       (447,341)  
Consolidated Statement of Operations and Comprehensive Loss for the three months ended September 30, 2022 (unaudited)                  
Research and development expenses       3,953       13,649  
Selling, general and administrative expenses       4,519       12,309  
Total operating expenses       8,472       25,958  
Operating loss       (7,801)       (24,327)  
Net loss       (8,505)       (26,365)  
Total other comprehensive loss       $ (8,551)       $ (26,447)  
Basic loss per common share (in dollars per share)       $ (0.92)       $ (3.09)  
Diluted loss per common share (in dollars per share)       $ (0.92)       $ (3.09)  
Consolidated statement of Stockholders’ Equity (Deficit) for the three months ended September 30, 2022 (unaudited)                  
Compensation expense for issuance of stock options       $ 1,255       $ 4,345  
Net loss       (8,505)       (26,365)  
Consolidated Statement of Cash Flows for the nine months ended September 30, 2022 (unaudited)                  
Net loss       (8,505)       (26,365)  
Stock option compensation expense               4,345  
Adjustment                  
Balance Sheet for September 30, 2022 (unaudited)                  
Additional paid-in capital       1,671       1,671  
Accumulated deficit       (1,671)       (1,671)  
Consolidated Statement of Operations and Comprehensive Loss for the three months ended September 30, 2022 (unaudited)                  
Research and development expenses       112       503  
Selling, general and administrative expenses       260       1,168  
Total operating expenses       372       1,671  
Operating loss       (372)       (1,671)  
Net loss       (372)       (1,671)  
Total other comprehensive loss       $ (372)       $ (1,671)  
Basic loss per common share (in dollars per share)       $ (0.04)       $ (0.20)  
Diluted loss per common share (in dollars per share)       $ (0.04)       $ (0.20)  
Consolidated statement of Stockholders’ Equity (Deficit) for the three months ended September 30, 2022 (unaudited)                  
Compensation expense for issuance of stock options       $ 372       $ 1,671  
Net loss       (372)       (1,671)  
Consolidated Statement of Cash Flows for the nine months ended September 30, 2022 (unaudited)                  
Net loss       (372)       (1,671)  
Stock option compensation expense               1,671  
As revised                  
Balance Sheet for September 30, 2022 (unaudited)                  
Additional paid-in capital       443,737       443,737  
Accumulated deficit       (449,012)       (449,012)  
Consolidated Statement of Operations and Comprehensive Loss for the three months ended September 30, 2022 (unaudited)                  
Research and development expenses       4,065       14,152  
Selling, general and administrative expenses       4,779       13,477  
Total operating expenses       8,844       27,629  
Operating loss       (8,173)       (25,998)  
Net loss       (8,877)       (28,036)  
Total other comprehensive loss       $ (8,923)       $ (28,118)  
Basic loss per common share (in dollars per share)       $ (0.96)       $ (3.29)  
Diluted loss per common share (in dollars per share)       $ (0.96)       $ (3.29)  
Consolidated statement of Stockholders’ Equity (Deficit) for the three months ended September 30, 2022 (unaudited)                  
Compensation expense for issuance of stock options       $ 1,627       $ 6,016  
Net loss       (8,877)       (28,036)  
Consolidated Statement of Cash Flows for the nine months ended September 30, 2022 (unaudited)                  
Net loss       $ (8,877)       (28,036)  
Stock option compensation expense               $ 6,016